Anti-α4β7 Integrin (Vedolizumab), Humanized Antibody

Anti-α4β7 Integrin (Vedolizumab), Humanized Antibodyis available at Gentaur for Next week Delivery.

Description: Vedolizumab is a recombinant humanized IgG1 monoclonal antibody that selectively targets α4β7 integrin expressed on the surface of T and B cell lymphocytes and prevents the association of the integrin with its ligand, mucosal addressin cell adhesion molecule-1 (MAdCAM-1). This inhibits the inflammatory activity of the lymphocytic cells and its migration into the gut lamina propria and gut-associated lymphoid tissue (GALT). Vedolizumab was developed by Millennium Pharmaceuticals and received FDA approval in 2014 for the treatment of ulcerative colitis and Crohn’s disease. Vedolizumab is marketed under the trade name of Entyvio®

Immunogen Sequence:Vedolizumab

Target Alternative Name:LDP 02, LDP-02, LDP02, MLN-0002, MLN-02, MLN0002, MLN02, ENTYVIO, α4β7, ITGA4/ITGB7

Species Reactivities:Human

Tag Line:Vedolizumab is a humanized monoclonal antibody that binds to α4β7 integrin expressed on the surface of T and B lymphocytes and prevents gastrointestinal inflammatory activity. The monoclonal antibody received approval from the FDA for the treatment of ulcerative colitis and Crohn's disease

Formulation:In PBS, pH 7.5

Purification: Protein A purified

Application:In vitro studies

Positive Control:/

Application And Usages:In vitro studies

Handling:The antibody solution should be gently mixed before use.